← All Signals

🏥 FDA: F.H. INVESTMENTS, Inc. (dba Asteria Health) — Class II

healthcarebearishSource: FDA
80%Confidence
0Views
FDASource
2026-03-05Date

Summary

Asteria Health's testosterone product recall due to potential metal particulate matter poses significant safety risks and regulatory compliance issues. This could lead to increased FDA oversight and potential legal liabilities for the company.

Actionable: Consider reducing exposure to Asteria Health and similar compounding pharmacies until quality control improvements are demonstrated.

AI Confidence: 80%

Data Points

firmF.H. INVESTMENTS, Inc. (dba Asteria Health)
classificationClass II
statusOngoing
distributionNationwide in the USA
productTestosterone, 100 mg, 1 Sterile Pellet, Asteria Health 432 Industrial Ln, Birmingham, AL 35211, NDC:79559-1100-32.

Get Signals Instantly

Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.

Subscribe Now